On 23–24 July 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) met to discuss seven peptide-related bulk drug substances nominated for the section 503A bulk drug substances list. This page follows the FDA meeting materials. FDA has not posted summary minutes or official yes/no/abstain tallies on the meeting page as of 8 October 2026, so this article does not invent vote counts. The meeting was advisory: it did not approve any drug, and it did not add any substance to the 503A or 503B lists.
Primary source: FDA advisory committee calendar — July 23–24, 2026 PCAC meeting. Docket: FDA-2025-N-6895. Final agenda: FDA final agenda PDF. Voting questions: FDA questions PDF.
Definition: PCAC is a federal advisory committee that gives FDA non-binding advice on compounding questions. For this meeting, FDA’s questions asked whether each nominated peptide (free base and acetate) should be placed on the 503A bulks list. A committee vote is advice to FDA, not list inclusion and not drug approval.
PCAC July 2026: What the July 2026 PCAC agenda covered (503A, not 503B)
FDA’s published agenda and voting questions framed every substance under section 503A of the Federal Food, Drug, and Cosmetic Act — the path for traditional compounding pharmacies preparing patient-specific prescriptions. This was not a meeting to add substances to the 503B outsourcing-facility bulks list. Describing the July 2026 review as a 503B listing event is incorrect.
Even if PCAC recommends inclusion, FDA must still decide whether to proceed with notice-and-comment rulemaking before any substance is added to the 503A bulks list (see 21 C.F.R. § 216.23 for how that list is maintained by regulation). As of this writing, FDA has not published a final rule from this meeting that places these peptides on either bulks list.
PCAC July 2026: Which seven peptides were on the July 2026 agenda?
FDA’s meeting page lists seven peptide-related nominations. Each was discussed as free base and acetate. The specific nominated uses FDA evaluated for each substance are set out in the FDA final agenda and briefing documents; listing them here is not an endorsement, and an agenda item is not a finding of safety or effectiveness.
| Bulk drug substance | Forms discussed | Agenda status |
|---|---|---|
| BPC-157 | Free base and acetate | 503A agenda item |
| KPV | Free base and acetate | 503A agenda item |
| TB-500 | Free base and acetate | 503A agenda item |
| MOTS-c | Free base and acetate | 503A agenda item |
| Emideltide / DSIP | Free base and acetate | 503A agenda item |
| Epitalon | Free base and acetate | 503A agenda item |
| Semax | Free base and acetate | 503A agenda item |
Not on that agenda: Selank, GHK-Cu, and Kisspeptin-10 do not appear on FDA’s July 23–24, 2026 PCAC meeting page. Older site copy that listed those three as PCAC “recommendations” was wrong and is removed here.
Vote tallies: FDA’s Event Materials for this meeting include briefing documents, the final agenda, the roster, and FDA presentations. They do not include published summary minutes or an official vote ledger as of 8 October 2026. This article therefore does not invent yes/no/abstain counts. Secondary reports exist; they are not FDA primary records.
PCAC July 2026: How the PCAC process works (high level)
- Nomination: Parties may nominate a bulk substance to CDER with proposed uses and supporting information.
- FDA review: FDA staff prepare briefing materials and may recommend for or against inclusion.
- PCAC meeting: The committee hears FDA presentations, nominator comments, and public comment, then votes on FDA’s questions.
- Advisory outcome: The vote is advice to FDA.
- FDA decision / rulemaking: Only a later FDA action (typically notice-and-comment rulemaking for the 503A bulks list) can change the list. The July 2026 meeting alone did not authorize compounding of these peptides under 503A or 503B.
PCAC July 2026: What this means for research-peptide procurement
Peptide.Express supplies research materials for laboratory use only. Neither a PCAC agenda item nor an advisory recommendation changes RUO sourcing rules, Certificates of Analysis, or the fact that research materials are not approved drugs. Buyers should continue to match lot numbers to batch CoAs and keep regulatory news separate from product analytics.
Useful FDA starting points after this meeting:
- The PCAC meeting page linked above (agenda, briefing documents, presentations).
- The Federal Register / Regulations.gov docket FDA-2025-N-6895 for public comments filed around the meeting.
- FDA’s pharmacy compounding resources for 503A vs 503B pathways.
